VTGN logo

VistaGen Therapeutics (VTGN) Cash From Operations

Annual CFO

-$25.81 M
+$23.90 M+48.08%

March 31, 2024


Summary


Performance

VTGN Cash From Operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherVTGNcash flowmetrics:

Quarterly CFO

-$10.89 M
-$17.00 K-0.16%

September 30, 2024


Summary


Performance

VTGN Quarterly CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherVTGNcash flowmetrics:

TTM CFO

-$33.49 M
-$4.70 M-16.31%

September 30, 2024


Summary


Performance

VTGN TTM CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherVTGNcash flowmetrics:

Cash From Operations Formula

CFO = Net Income + Non Cash Expenses + Changes In Working Capital

VTGN Cash From Operations Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+48.1%0.0%0.0%
3 y3 years-113.8%0.0%0.0%
5 y5 years-77.7%0.0%0.0%

VTGN Cash From Operations Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-113.8%+48.1%-140.1%+33.4%-29.7%+44.1%
5 y5-year-113.8%+48.1%-1184.6%+33.4%-286.6%+44.1%
alltimeall time<-9999.0%+48.1%-1184.6%+33.4%<-9999.0%+44.1%

VistaGen Therapeutics Cash From Operations History

DateAnnualQuarterlyTTM
Sep 2024
-
-$10.89 M(+0.2%)
-$33.49 M(+16.3%)
Jun 2024
-
-$10.87 M(+51.0%)
-$28.79 M(+11.5%)
Mar 2024
-$25.81 M(-48.1%)
-$7.20 M(+58.7%)
-$25.81 M(-1.1%)
Dec 2023
-
-$4.53 M(-26.7%)
-$26.09 M(-17.1%)
Sep 2023
-
-$6.19 M(-21.6%)
-$31.49 M(-24.4%)
Jun 2023
-
-$7.89 M(+5.6%)
-$41.64 M(-16.2%)
Mar 2023
-$49.72 M(+9.9%)
-$7.47 M(-24.8%)
-$49.72 M(-14.0%)
Dec 2022
-
-$9.93 M(-39.2%)
-$57.83 M(-3.5%)
Sep 2022
-
-$16.34 M(+2.3%)
-$59.94 M(+8.9%)
Jun 2022
-
-$15.97 M(+2.4%)
-$55.05 M(+21.6%)
Mar 2022
-$45.26 M(+274.8%)
-$15.59 M(+29.4%)
-$45.26 M(+29.5%)
Dec 2021
-
-$12.05 M(+5.2%)
-$34.95 M(+25.3%)
Sep 2021
-
-$11.45 M(+85.5%)
-$27.89 M(+80.7%)
Jun 2021
-
-$6.17 M(+16.9%)
-$15.44 M(+27.9%)
Mar 2021
-$12.07 M(-23.4%)
-$5.28 M(+5.9%)
-$12.07 M(+28.8%)
Dec 2020
-
-$4.99 M(-597.0%)
-$9.37 M(+8.2%)
Sep 2020
-
$1.00 M(-135.8%)
-$8.66 M(-37.2%)
Jun 2020
-
-$2.81 M(+8.8%)
-$13.80 M(-12.4%)
Mar 2020
-$15.76 M(+8.5%)
-$2.58 M(-39.7%)
-$15.76 M(-5.8%)
Dec 2019
-
-$4.28 M(+3.5%)
-$16.73 M(+2.3%)
Sep 2019
-
-$4.14 M(-13.1%)
-$16.36 M(+1.3%)
Jun 2019
-
-$4.76 M(+33.9%)
-$16.15 M(+11.2%)
Mar 2019
-$14.53 M(+60.4%)
-$3.56 M(-9.0%)
-$14.53 M(+7.0%)
Dec 2018
-
-$3.91 M(-0.5%)
-$13.57 M(+12.1%)
Sep 2018
-
-$3.93 M(+25.3%)
-$12.11 M(+20.4%)
Jun 2018
-
-$3.14 M(+20.4%)
-$10.06 M(+11.1%)
Mar 2018
-$9.06 M(+24.7%)
-$2.60 M(+6.5%)
-$9.06 M(+16.9%)
Dec 2017
-
-$2.44 M(+30.3%)
-$7.75 M(+4.7%)
Sep 2017
-
-$1.88 M(-12.1%)
-$7.40 M(-4.2%)
Jun 2017
-
-$2.13 M(+64.9%)
-$7.73 M(+6.4%)
Mar 2017
-$7.26 M(+51.0%)
-$1.29 M(-38.2%)
-$7.26 M(-0.2%)
Dec 2016
-
-$2.10 M(-4.9%)
-$7.28 M(+14.6%)
Sep 2016
-
-$2.20 M(+31.8%)
-$6.35 M(+12.3%)
Jun 2016
-
-$1.67 M(+27.6%)
-$5.66 M(+17.6%)
DateAnnualQuarterlyTTM
Mar 2016
-$4.81 M(+73.7%)
-$1.31 M(+12.0%)
-$4.81 M(+9.4%)
Dec 2015
-
-$1.17 M(-22.4%)
-$4.39 M(+23.2%)
Sep 2015
-
-$1.51 M(+82.9%)
-$3.56 M(+38.2%)
Jun 2015
-
-$823.30 K(-8.0%)
-$2.58 M(-6.8%)
Mar 2015
-$2.77 M(+30.2%)
-$894.50 K(+162.3%)
-$2.77 M(+18.3%)
Dec 2014
-
-$341.00 K(-34.6%)
-$2.34 M(-0.1%)
Sep 2014
-
-$521.60 K(-48.4%)
-$2.34 M(-2.6%)
Jun 2014
-
-$1.01 M(+116.6%)
-$2.41 M(+13.2%)
Mar 2014
-$2.13 M(-38.6%)
-$467.10 K(+36.4%)
-$2.13 M(-19.1%)
Dec 2013
-
-$342.50 K(-41.4%)
-$2.63 M(-19.1%)
Sep 2013
-
-$584.60 K(-20.1%)
-$3.25 M(-16.7%)
Jun 2013
-
-$731.80 K(-24.6%)
-$3.90 M(+12.6%)
Mar 2013
-$3.46 M(-2.9%)
-$970.00 K(+0.8%)
-$3.46 M(+7.8%)
Dec 2012
-
-$962.60 K(-22.0%)
-$3.21 M(-2.9%)
Sep 2012
-
-$1.23 M(+316.7%)
-$3.31 M(+19.2%)
Jun 2012
-
-$296.20 K(-58.8%)
-$2.78 M(-22.2%)
Mar 2012
-$3.57 M(>+9900.0%)
-$718.60 K(-32.1%)
-$3.57 M(+25.2%)
Dec 2011
-
-$1.06 M(+50.7%)
-$2.85 M(+58.9%)
Sep 2011
-
-$702.20 K(-35.4%)
-$1.79 M(+64.4%)
Jun 2011
-
-$1.09 M(>+9900.0%)
-$1.09 M(>+9900.0%)
Mar 2011
-
-$1700.00(-19.0%)
-$8600.00(+24.6%)
Dec 2010
-$6900.00(-69.7%)
-$2100.00(+2000.0%)
-$6900.00(-5.5%)
Sep 2010
-
-$100.00(-97.9%)
-$7300.00(+1.4%)
Jun 2010
-
-$4700.00(<-9900.0%)
-$7200.00(+50.0%)
Mar 2010
-
$0.00(-100.0%)
-$4800.00(-78.9%)
Dec 2009
-$22.80 K(+58.3%)
-$2500.00(<-9900.0%)
-$22.80 K(-33.5%)
Sep 2009
-
$0.00(-100.0%)
-$34.30 K(-0.3%)
Jun 2009
-
-$2300.00(-87.2%)
-$34.40 K(+6.8%)
Mar 2009
-
-$18.00 K(+28.6%)
-$32.20 K(+122.1%)
Dec 2008
-$14.40 K
-$14.00 K(>+9900.0%)
-$14.50 K(+2800.0%)
Sep 2008
-
-$100.00(0.0%)
-$500.00(+25.0%)
Jun 2008
-
-$100.00(-66.7%)
-$400.00(+33.3%)
Mar 2008
-
-$300.00(-86.4%)
-$300.00(-86.4%)
Mar 2007
-
-$2200.00
-$2200.00

FAQ

  • What is VistaGen Therapeutics annual cash flow from operations?
  • What is the all time high annual CFO for VistaGen Therapeutics?
  • What is VistaGen Therapeutics annual CFO year-on-year change?
  • What is VistaGen Therapeutics quarterly cash flow from operations?
  • What is the all time high quarterly CFO for VistaGen Therapeutics?
  • What is VistaGen Therapeutics quarterly CFO year-on-year change?
  • What is VistaGen Therapeutics TTM cash flow from operations?
  • What is the all time high TTM CFO for VistaGen Therapeutics?
  • What is VistaGen Therapeutics TTM CFO year-on-year change?

What is VistaGen Therapeutics annual cash flow from operations?

The current annual CFO of VTGN is -$25.81 M

What is the all time high annual CFO for VistaGen Therapeutics?

VistaGen Therapeutics all-time high annual cash flow from operations is -$6900.00

What is VistaGen Therapeutics annual CFO year-on-year change?

Over the past year, VTGN annual cash flow from operations has changed by +$23.90 M (+48.08%)

What is VistaGen Therapeutics quarterly cash flow from operations?

The current quarterly CFO of VTGN is -$10.89 M

What is the all time high quarterly CFO for VistaGen Therapeutics?

VistaGen Therapeutics all-time high quarterly cash flow from operations is $1.00 M

What is VistaGen Therapeutics quarterly CFO year-on-year change?

Over the past year, VTGN quarterly cash flow from operations has changed by $0.00 (0.00%)

What is VistaGen Therapeutics TTM cash flow from operations?

The current TTM CFO of VTGN is -$33.49 M

What is the all time high TTM CFO for VistaGen Therapeutics?

VistaGen Therapeutics all-time high TTM cash flow from operations is -$300.00

What is VistaGen Therapeutics TTM CFO year-on-year change?

Over the past year, VTGN TTM cash flow from operations has changed by $0.00 (0.00%)